We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

6 hedge funds and large institutions have $1.9M invested in Loncar China BioPharma ETF in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 3 → 6 (+3)

100% more capital invested

Capital invested by funds: $948K → $1.9M (+$947K)

Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$637K
2
FEM
Fulcrum Equity Management
Texas
+$301K
3
Osaic Holdings
Osaic Holdings
Arizona
+$21.6K
4
UBS Group
UBS Group
Switzerland
+$17.1K
5
TRCT
Tower Research Capital (TRC)
New York
+$126

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
$1.49M +$637K +20,148 +71%
FEM
2
Fulcrum Equity Management
Texas
$292K +$301K +9,504 New
Morgan Stanley
3
Morgan Stanley
New York
$61K – – –
UBS Group
4
UBS Group
Switzerland
$27K +$17.1K +541 +158%
Osaic Holdings
5
Osaic Holdings
Arizona
$21K +$21.6K +684 New
TRCT
6
Tower Research Capital (TRC)
New York
– +$126 +4 New

CHNA Hedge Fund Activity: Q3 2020 in Review

6 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q3 2020, worth a combined $1.9M — up 100% from $948K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CHNA positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Jane Street, adding an estimated $637K.

  • 6 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q3 2020, up from 3 in Q2 2020.
  • Funds reported $1.9M of Loncar China BioPharma ETF stock for Q3 2020, up 100% quarter-over-quarter.
  • 3 funds opened new Loncar China BioPharma ETF positions in Q3 2020 and 0 closed out, a net change of +3 holders.
  • The largest Loncar China BioPharma ETF buyer in Q3 2020 was Jane Street, an estimated $637K added.

Based on aggregated 13F filings for Q3 2020.